US794392A
(en)
*
|
1904-01-29 |
1905-07-11 |
Nat Tube Co |
Bending-roll.
|
US4482571A
(en)
|
1982-06-21 |
1984-11-13 |
University Of Pittsburgh |
Sickle cell anemia treatment and compound
|
GB8524157D0
(en)
|
1984-10-19 |
1985-11-06 |
Ici America Inc |
Heterocyclic amides
|
GB8607294D0
(en)
|
1985-04-17 |
1986-04-30 |
Ici America Inc |
Heterocyclic amide derivatives
|
IE862737L
(en)
|
1985-10-17 |
1987-04-17 |
Staehler Theo |
Heterocyclic compounds
|
US4964895A
(en)
|
1987-06-08 |
1990-10-23 |
Monsanto Company |
Substituted 4-(4-nitrophenoxy) pyrazoles and their use as herbicides
|
US4997815A
(en)
|
1988-11-01 |
1991-03-05 |
Children's Hospital Medical Center Of Northern California |
Method for augmenting fetal hemoglobin by treatment with activin and/or inhibin
|
WO1990009381A1
(en)
|
1989-02-08 |
1990-08-23 |
Abbott Laboratories |
4-hydroxythiazoles as 5-lipoxygenase inhibitors
|
US5216004A
(en)
|
1990-09-13 |
1993-06-01 |
Children's Hospital Medical Center Of North California |
Method for preventing malaria
|
US5656644A
(en)
|
1994-07-20 |
1997-08-12 |
Smithkline Beecham Corporation |
Pyridyl imidazoles
|
US5439939A
(en)
|
1992-03-17 |
1995-08-08 |
Children's Hospital Medical Center Of Northern California |
Pharmaceutical compositions and methods using isobutyramide for treating betaglobin disorders
|
EP0731712A4
(en)
|
1993-10-29 |
2005-11-09 |
Univ Boston |
PHYSIOLOGICAL STABILIZED BUTTERIC ACID PREPARATIONS, AND BUTTERIC ACIDS AND DERIVATIVES AS ANTINEOPLASTIC ACTIVE SUBSTANCE
|
AU679818B2
(en)
|
1993-11-10 |
1997-07-10 |
Sloan-Kettering Institute For Cancer Research |
Butyric ester cyto-differentiating agents
|
US5569675A
(en)
|
1994-03-07 |
1996-10-29 |
Bar Ilan University |
Methods of using carboxylic acid esters to increase fetal-hemoglobin levels
|
US6071923A
(en)
|
1994-09-16 |
2000-06-06 |
Bar-Ilan University |
Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
US6040342A
(en)
|
1994-09-16 |
2000-03-21 |
Bar-Ilan University |
Retinoyloxy (alkyl-substituted) methyl butyrates useful for the treatment of cancer and other proliferative diseases
|
US5789434A
(en)
|
1994-11-15 |
1998-08-04 |
Bayer Corporation |
Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
|
US6011000A
(en)
|
1995-03-03 |
2000-01-04 |
Perrine; Susan P. |
Compositions for the treatment of blood disorders
|
US5700826A
(en)
|
1995-06-07 |
1997-12-23 |
Ontogen Corporation |
1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
|
JP3964478B2
(ja)
|
1995-06-30 |
2007-08-22 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
|
US5922837A
(en)
|
1995-09-20 |
1999-07-13 |
Merck & Co., Inc. |
Antiprotozoal cyclic tetrapeptides
|
US6110697A
(en)
|
1995-09-20 |
2000-08-29 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
WO1997011366A1
(en)
|
1995-09-20 |
1997-03-27 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
US20030219832A1
(en)
|
1996-03-11 |
2003-11-27 |
Klein Elliott S. |
Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
|
US6777217B1
(en)
|
1996-03-26 |
2004-08-17 |
President And Fellows Of Harvard College |
Histone deacetylases, and uses related thereto
|
WO1997047307A1
(en)
|
1996-06-14 |
1997-12-18 |
The Uab Research Foundation |
Use of histone deacetylase inhibitors to activate transgene expression
|
CA2258593A1
(en)
|
1996-07-02 |
1998-01-08 |
Abraham Nudelman |
Retinoyloxy(substituted)alkylene butyrates useful for the treatment of cancer and other proliferative diseases
|
US6197743B1
(en)
|
1996-07-26 |
2001-03-06 |
The Trustees Of Boston University |
Compositions and methods for the treatment of viral disorders
|
US5939456A
(en)
|
1996-07-26 |
1999-08-17 |
Perrine; Susan P. |
Pulsed administration of compositions for the treatment of blood disorders
|
EP0827742A1
(en)
|
1996-09-04 |
1998-03-11 |
Vrije Universiteit Brussel |
Use of histone deacetylase inhibitors for treating fribosis or cirrhosis
|
US6068987A
(en)
|
1996-09-20 |
2000-05-30 |
Merck & Co., Inc. |
Histone deacetylase as target for antiprotozoal agents
|
US6794392B1
(en)
|
1996-09-30 |
2004-09-21 |
Schering Aktiengesellschaft |
Cell differentiation inducer
|
US6174905B1
(en)
|
1996-09-30 |
2001-01-16 |
Mitsui Chemicals, Inc. |
Cell differentiation inducer
|
CN1246847A
(zh)
|
1996-12-23 |
2000-03-08 |
杜邦药品公司 |
作为Xa因子抑制剂的含氮杂芳族化合物
|
US6235474B1
(en)
|
1996-12-30 |
2001-05-22 |
The Johns Hopkins University |
Methods and kits for diagnosing and determination of the predisposition for diseases
|
US6130248A
(en)
|
1996-12-30 |
2000-10-10 |
Bar-Ilan University |
Tricarboxylic acid-containing oxyalkyl esters and uses thereof
|
WO1998029114A1
(en)
|
1996-12-30 |
1998-07-09 |
Bar-Ilan University |
Tricarboxylic acid-containing oxyalkyl esters and uses thereof
|
US7062219B2
(en)
|
1997-01-31 |
2006-06-13 |
Odyssey Thera Inc. |
Protein fragment complementation assays for high-throughput and high-content screening
|
US6043389A
(en)
|
1997-03-11 |
2000-03-28 |
Mor Research Applications, Ltd. |
Hydroxy and ether-containing oxyalkylene esters and uses thereof
|
US6110955A
(en)
|
1997-03-11 |
2000-08-29 |
Beacon Laboratories, Inc. |
Metabolically stabilized oxyalkylene esters and uses thereof
|
US6110970A
(en)
|
1997-03-11 |
2000-08-29 |
Beacon Laboratories, Inc. |
Nitrogen-containing oxyalkylene esters and uses thereof
|
US5939455A
(en)
|
1997-03-11 |
1999-08-17 |
Beacon Laboratories, Inc. |
Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
|
US6124495A
(en)
|
1997-03-11 |
2000-09-26 |
Beacon Laboratories, Inc. |
Unsaturated oxyalkylene esters and uses thereof
|
US6030961A
(en)
|
1997-03-11 |
2000-02-29 |
Bar-Ilan Research & Development Co., Ltd. |
Oxyalkylene phosphate compounds and uses thereof
|
US6387673B1
(en)
|
1997-05-01 |
2002-05-14 |
The Salk Institute For Biological Studies |
Compounds useful for the modulation of processes mediated by nuclear hormone receptors, methods for the identification and use of such compounds
|
US6231880B1
(en)
|
1997-05-30 |
2001-05-15 |
Susan P. Perrine |
Compositions and administration of compositions for the treatment of blood disorders
|
AUPO721997A0
(en)
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
AUPO864097A0
(en)
|
1997-08-19 |
1997-09-11 |
Peplin Pty Ltd |
Anti-cancer compounds
|
JP3494624B2
(ja)
|
1997-09-02 |
2004-02-09 |
住友製薬株式会社 |
新規な環状テトラペプチド誘導体とその医薬用途
|
WO1999023885A1
(en)
|
1997-11-10 |
1999-05-20 |
The Salk Institute For Biological Studies |
Methods for the use of inhibitors of co-repressors for the treatment of neoplastic diseases
|
US6884597B1
(en)
|
1998-01-20 |
2005-04-26 |
Medical & Biological Laboratories, Co., Ltd. |
Method for detecting acetyltransferase and deacetylase activities and method for screening inhibitors or enhancers of these enzymes
|
US6262116B1
(en)
|
1998-01-23 |
2001-07-17 |
Sloan-Kettering Institute For Cancer Research |
Transcription therapy for cancers
|
CA2324426A1
(en)
|
1998-02-11 |
1999-08-19 |
Douglas V. Faller |
Compositions and methods for the treatment of cystic fibrosis
|
US6287843B1
(en)
|
1998-04-03 |
2001-09-11 |
Pioneer Hi-Bred International, Inc. |
Maize histone deacetylases and their use
|
US6288063B1
(en)
|
1998-05-27 |
2001-09-11 |
Bayer Corporation |
Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
|
US20030236204A1
(en)
|
2002-06-14 |
2003-12-25 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 2 expression
|
AUPP505798A0
(en)
|
1998-08-04 |
1998-08-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel compound fr225497 substance
|
EP1105143A4
(en)
|
1998-08-21 |
2002-07-17 |
Smithkline Beecham Corp |
HUMAN GENE OF HISTONE DEACETYLASE HD4
|
DE19842506A1
(de)
|
1998-09-17 |
2000-03-23 |
Volkswagen Ag |
Verfahren und Vorrichtung zur Überwachung von Signalen bei vernetzten Systemen
|
CZ20011342A3
(cs)
|
1998-10-13 |
2001-09-12 |
Fujisawa Pharmaceutical Co., Ltd. |
Cyklické tetrapeptidy
|
CA2346152A1
(en)
|
1998-10-16 |
2000-04-27 |
Novartis Ag |
Promotion of self-renewal and improved gene transduction of hematopoietic stem cells by histone deacetylase inhibitors
|
US6372957B1
(en)
|
1998-11-10 |
2002-04-16 |
Board Of Regents, The University Of Texas System |
Transgenic mouse comprising a MEF2 binding site operatively linked to an indicator gene and methods of use
|
US6287790B1
(en)
|
1998-11-30 |
2001-09-11 |
The Regents Of The University Of California |
Utilization of nuclear structural proteins for targeted therapy and detection of proliferative and differentiation disorders
|
AU3316600A
(en)
|
1999-02-22 |
2000-09-21 |
Torben F. Orntoft |
Gene expression in bladder tumors
|
JP4269041B2
(ja)
|
1999-03-02 |
2009-05-27 |
国立大学法人九州工業大学 |
新規な環状テトラペプチド誘導体とその医薬用途
|
US7407745B1
(en)
|
1999-03-23 |
2008-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method for screening anticancer agent
|
US6518012B1
(en)
|
1999-04-02 |
2003-02-11 |
Health Research, Inc. |
Method for regulating the expression of MHC antigens and CD40 by inhibitors of histone deacetylation
|
JP2002541253A
(ja)
|
1999-04-09 |
2002-12-03 |
スミスクライン・ビーチャム・コーポレイション |
トリアリールイミダゾール
|
US20030078216A1
(en)
|
1999-05-03 |
2003-04-24 |
Macleod A. Robert |
Inhibition of histone deactylase
|
CA2366408A1
(en)
|
1999-05-03 |
2000-11-30 |
Methylgene, Inc. |
Inhibition of histone deacetylase
|
US20030078369A1
(en)
|
1999-07-23 |
2003-04-24 |
Meinke Peter T. |
Apicidin-derived cyclic tetrapeptides
|
EP1204411A1
(en)
|
1999-07-23 |
2002-05-15 |
Merck & Co., Inc. |
Apicidin-derived cyclic tetrapeptides
|
AU6794700A
(en)
|
1999-08-20 |
2001-03-19 |
Board Of Regents, The University Of Texas System |
Methods and compositions relating to hdac 4 and 5 regulation of cardiac gene expression
|
JP2001081031A
(ja)
|
1999-08-30 |
2001-03-27 |
Schering Ag |
溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
|
AU7108400A
(en)
|
1999-09-03 |
2001-04-10 |
Salk Institute For Biological Studies, The |
Modulation of gene expression by modulating histone acetylation
|
EA200601252A1
(ru)
|
1999-09-08 |
2006-10-27 |
Слоан-Кеттеринг Инститьют Фор Кэнсер Рисёч |
Новый класс веществ, вызывающих дифференцировку клеток и являющихся ингибиторами гистондеацетилазы, и способы их применения
|
ATE361316T1
(de)
|
1999-09-08 |
2007-05-15 |
Sloan Kettering Inst Cancer |
Kristallstruktur einer deacetylase und deren inhibitoren
|
JP2003511054A
(ja)
|
1999-10-08 |
2003-03-25 |
メルク エンド カムパニー インコーポレーテッド |
抗原虫ヒストンアセチルトランスフェラーゼインヒビター
|
AU783504C
(en)
|
1999-11-23 |
2006-08-03 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
JP2001149081A
(ja)
|
1999-11-29 |
2001-06-05 |
Cyclex Co Ltd |
脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
|
CA2291367A1
(en)
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
US6828302B1
(en)
|
1999-12-08 |
2004-12-07 |
Xcyte Therapies, Inc. |
Therapeutic uses of depsipeptides and congeners thereof
|
US6875598B1
(en)
|
1999-12-08 |
2005-04-05 |
Applera Corporation |
Histone deacetylase-8 proteins, nuclei acids, and methods for use
|
ATE353663T1
(de)
|
1999-12-08 |
2007-03-15 |
Cyclacel Pharmaceuticals Inc |
Verwendung von depsipeptide und deren analoge als immunosuppressiva zur behandlung von infektionskrankheiten, autoimmunerkrankungen, allergien und hyperproliferativer hautkrankheiten
|
WO2001042437A2
(en)
|
1999-12-08 |
2001-06-14 |
Axys Pharmaceuticals, Inc. |
Histone deacetylase-8 proteins, nucleic acids, and methods of use
|
US7452664B2
(en)
|
1999-12-15 |
2008-11-18 |
Massachusetts Institute Of Technology |
Methods for identifying agents which alter histone protein acetylation
|
US6544957B2
(en)
|
2000-01-04 |
2003-04-08 |
The Johns Hopkins University |
Methods and reagents for facilitating transcription
|
EP1254369B1
(en)
|
2000-02-08 |
2010-10-06 |
Sangamo BioSciences, Inc. |
Cells for drug discovery
|
CA2401778C
(en)
|
2000-02-29 |
2010-12-21 |
Cor Therapeutics, Inc. |
Benzamides and related inhibitors of factor xa
|
US20030129724A1
(en)
|
2000-03-03 |
2003-07-10 |
Grozinger Christina M. |
Class II human histone deacetylases, and uses related thereto
|
GB0005199D0
(en)
|
2000-03-04 |
2000-04-26 |
Imp College Innovations Ltd |
Modulation of histone deacetylase
|
GB0007217D0
(en)
|
2000-03-24 |
2000-05-17 |
Europ I Of Oncology |
Materials and methods relating to the treatment of leukaemias
|
ATE489360T1
(de)
|
2000-03-24 |
2010-12-15 |
Methylgene Inc |
Inhibitoren der histon-deacetylase
|
US20020137162A1
(en)
|
2000-03-24 |
2002-09-26 |
Zuomei Li |
Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
|
CA2404100A1
(en)
|
2000-03-24 |
2001-10-04 |
Filgen Biosciences, Inc. |
Therapeutic peptides having a motif that binds specifically to non-acetylated h3 and h4 histones for cancer therapy
|
JP2004533850A
(ja)
|
2000-03-24 |
2004-11-11 |
メチルジーン・インコーポレーテッド |
特異的なヒストン脱アセチル化酵素アイソフォームの阻害
|
GB0007405D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Corp |
Compounds
|
US6458589B1
(en)
|
2000-04-27 |
2002-10-01 |
Geron Corporation |
Hepatocyte lineage cells derived from pluripotent stem cells
|
EP1170008A1
(en)
|
2000-07-07 |
2002-01-09 |
Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus |
Valproic acid and derivatives thereof as histone deacetylase inhibitors
|
ATE425177T1
(de)
|
2000-07-17 |
2009-03-15 |
Astellas Pharma Inc |
Reduziertes fk228 und seine verwendung
|
US20020164752A1
(en)
|
2000-07-21 |
2002-11-07 |
Meyers Rachel A. |
47508, a novel human histone deacetylase family member and uses thereof
|
KR20030031132A
(ko)
|
2000-07-28 |
2003-04-18 |
스미또모 세이야꾸 가부시키가이샤 |
피롤 유도체
|
US6673587B1
(en)
|
2000-08-11 |
2004-01-06 |
The Salk Institute For Biological Studies |
Histone deacetylase, and uses therefor
|
EP1182263A1
(en)
|
2000-08-11 |
2002-02-27 |
Evotec OAI AG |
Process for detecting threonine/serine kinase activity
|
WO2002015921A2
(en)
|
2000-08-18 |
2002-02-28 |
The Governement Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
|
PE20020354A1
(es)
|
2000-09-01 |
2002-06-12 |
Novartis Ag |
Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
|
US20050004007A1
(en)
|
2000-09-12 |
2005-01-06 |
Steven Grant |
Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitiors and cellular differentiation agents
|
US6538030B2
(en)
|
2000-09-20 |
2003-03-25 |
Yih-Lin Chung |
Treating radiation fibrosis
|
US7569724B2
(en)
|
2000-09-29 |
2009-08-04 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an amide linkage as HDAC inhibitors
|
CA2423744C
(en)
|
2000-09-29 |
2012-04-03 |
Prolifix Limited |
Hydroxamic acid compounds comprising a sulfonamide linkage as hdac inhibitors
|
GB0023983D0
(en)
|
2000-09-29 |
2000-11-15 |
Prolifix Ltd |
Therapeutic compounds
|
AU2002215018A1
(en)
|
2000-10-13 |
2002-04-22 |
Bayer Aktiengesellschaft |
Human histone deacetylase gene
|
DE10053474A1
(de)
|
2000-10-24 |
2002-05-02 |
Schering Ag |
Schwefelhaltige Indirubinderivate, deren Herstellung und Verwendung
|
US20020103192A1
(en)
|
2000-10-26 |
2002-08-01 |
Curtin Michael L. |
Inhibitors of histone deacetylase
|
US20040043470A1
(en)
|
2000-10-31 |
2004-03-04 |
Yonghong Xiao |
Regulation of human histone deacetylase
|
JP4406205B2
(ja)
|
2000-11-02 |
2010-01-27 |
スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ |
Hsp90に結合するための小分子組成物
|
WO2002055017A2
(en)
|
2000-11-21 |
2002-07-18 |
Wake Forest University |
Method of treating autoimmune diseases
|
DE10061162A1
(de)
|
2000-11-30 |
2002-07-11 |
Schering Ag |
Aryl-substituierte Indirubinderivate, deren Herstellung und Verwendung
|
AR035659A1
(es)
|
2000-12-07 |
2004-06-23 |
Hoffmann La Roche |
Hidroxiamidas de acido (1-oxo-1,2,3,4-tetrahidro-naftalen-2-il)-alcanoico, proceso para la manufactura de estos compuestos, composiciones farmaceuticas que contienen dichos compuestos y los usos de los mismos
|
US20040005574A1
(en)
|
2002-07-08 |
2004-01-08 |
Leonard Guarente |
SIR2 activity
|
US6376508B1
(en)
|
2000-12-13 |
2002-04-23 |
Academia Sinica |
Treatments for spinal muscular atrophy
|
AU2002230997A1
(en)
|
2000-12-15 |
2002-06-24 |
Genetics Institute, Llc |
Methods and compositions for diagnosing and treating rheumatoid arthritis
|
US20040204373A1
(en)
|
2000-12-19 |
2004-10-14 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase I expression
|
US20050171042A1
(en)
|
2000-12-19 |
2005-08-04 |
Monia Brett P. |
Compositions and their uses directed to binding proteins
|
JP2004520027A
(ja)
|
2000-12-20 |
2004-07-08 |
ノバルティス アクチエンゲゼルシャフト |
ヒストンデアセチラーゼ関連遺伝子およびタンパク質
|
US6693132B2
(en)
|
2000-12-21 |
2004-02-17 |
Beacon Laboratories, Inc. |
Methods for using alkanoyloxymethyl esters
|
US6720445B2
(en)
|
2000-12-21 |
2004-04-13 |
Beacon Laboratories, Inc. |
Acetyloxymethyl esters and methods for using the same
|
US6562995B1
(en)
|
2000-12-21 |
2003-05-13 |
Beacon Laboratories, Inc. |
Delta dicarbonyl compounds and methods for using the same
|
JP2004516328A
(ja)
|
2000-12-22 |
2004-06-03 |
ヒャン ウー リー |
アピシジン誘導体、その合成方法、及び該誘導体を含む抗癌剤組成物
|
AR035513A1
(es)
|
2000-12-23 |
2004-06-02 |
Hoffmann La Roche |
Derivados de tetrahidropiridina, proceso para prepararlos, composiciones farmaceuticas que los contienen, y uso de dichos compuestos en la preparacion de medicamentos
|
EP1356053A2
(en)
|
2001-01-10 |
2003-10-29 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
|
CA2434601A1
(en)
|
2001-01-12 |
2002-09-12 |
Methylgene, Inc. |
Methods for specifically inhibiting histone deacetylase-4
|
US20030152557A1
(en)
|
2001-01-12 |
2003-08-14 |
Besterman Jeffrey M. |
Methods for inhibiting histone deacetylase-4
|
US20030148970A1
(en)
|
2001-01-12 |
2003-08-07 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-4
|
US6756200B2
(en)
|
2001-01-26 |
2004-06-29 |
The Johns Hopkins University School Of Medicine |
Aberrantly methylated genes as markers of breast malignancy
|
AR035417A1
(es)
|
2001-01-27 |
2004-05-26 |
Hoffmann La Roche |
Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
|
US20020183388A1
(en)
|
2001-02-01 |
2002-12-05 |
Gudas Lorraine J. |
Use of retinoids plus histone deacetylase inhibitors to inhibit the growth of solid tumors
|
AU2002233314A1
(en)
|
2001-02-05 |
2002-09-19 |
Bayer Aktiengesellschaft |
Regulation of human histone acetyltransferase
|
US20020177594A1
(en)
|
2001-03-14 |
2002-11-28 |
Curtin Michael L. |
Inhibitors of histone deacetylase
|
US6495719B2
(en)
|
2001-03-27 |
2002-12-17 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
US8026280B2
(en)
|
2001-03-27 |
2011-09-27 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
WO2002076941A2
(en)
|
2001-03-27 |
2002-10-03 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
US7312247B2
(en)
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
EP1249246B1
(en)
|
2001-04-10 |
2005-09-28 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Use of an histone deacetylase inhibitor for the treatment of diseases associated with an hpv infection
|
AR035455A1
(es)
|
2001-04-23 |
2004-05-26 |
Hoffmann La Roche |
Derivados triciclicos de alquilhidroxamato , procesos para su elaboracion, composiciones farmaceuticas que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
ES2310213T3
(es)
|
2001-05-02 |
2009-01-01 |
The Regents Of The University Of California |
Procedimiento para tratar trastornos neurodegenerativos, psiquiatricos y otros trastornos con inhibidores de desacetilasa.
|
US7244853B2
(en)
|
2001-05-09 |
2007-07-17 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
WO2002089782A2
(en)
|
2001-05-09 |
2002-11-14 |
President And Fellows Of Harvard College |
Dioxanes and uses thereof
|
AU2002318364A1
(en)
|
2001-06-14 |
2003-01-02 |
Bristol-Myers Squibb Company |
Novel human histone deacetylases
|
US7063973B2
(en)
|
2001-06-14 |
2006-06-20 |
Sloan-Kettering Institute For Cancer Research |
HDAC9 polypeptides and polynucleotides and uses thereof
|
US6784173B2
(en)
|
2001-06-15 |
2004-08-31 |
Hoffmann-La Roche Inc. |
Aromatic dicarboxylic acid derivatives
|
WO2002102981A2
(en)
|
2001-06-15 |
2002-12-27 |
The Trustees Of Columbia University In The City Of New York |
SIR2α-BASED THERAPEUTIC AND PROPHYLACTIC METHODS
|
EP1407049A4
(en)
|
2001-06-19 |
2005-03-23 |
David Gladstone Inst |
HISTONE-DEACETYLASE AND METHODS OF USING SAME
|
CA2451654A1
(en)
|
2001-06-22 |
2003-01-03 |
Ceres, Inc. |
Chimeric histone acetyltransferase polypeptides
|
WO2003004050A1
(en)
|
2001-07-03 |
2003-01-16 |
University Of Virginia Patent Foundation |
Methylation of histone h4 at arginine 3
|
AU2002333315A1
(en)
|
2001-08-03 |
2003-02-24 |
Novartis Ag |
Human histone deacetylase-related gene and protein hdac10
|
US20040266718A1
(en)
|
2001-08-06 |
2004-12-30 |
Zuomei Li |
Inhibition of specific histone deacetylase isoforms
|
AR034897A1
(es)
|
2001-08-07 |
2004-03-24 |
Hoffmann La Roche |
Derivados n-monoacilados de o-fenilendiaminas, sus analogos heterociclicos de seis miembros y su uso como agentes farmaceuticos
|
ITMI20011733A1
(it)
|
2001-08-07 |
2003-02-07 |
Italfarmaco Spa |
Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc
|
PT1426054E
(pt)
|
2001-08-21 |
2011-12-06 |
Astellas Pharma Inc |
Utilização medicinal de inibidor da histona desacetilase e método de avaliação do seu efeito antitumoral
|
US20040259772A1
(en)
|
2001-08-24 |
2004-12-23 |
Antonio Fojo |
Use of a histone deacetylase inhibitor to increase the entry of an adenoviral agent into a cell
|
EP1291015A1
(en)
|
2001-09-10 |
2003-03-12 |
Lunamed AG |
Dosage forms having prolonged active ingredient release
|
US7868204B2
(en)
|
2001-09-14 |
2011-01-11 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|
KR20100107509A
(ko)
|
2001-09-14 |
2010-10-05 |
9222-9129 퀘벡 인코포레이티드 |
히스톤 데아세틸라아제의 억제제
|
US6897220B2
(en)
|
2001-09-14 |
2005-05-24 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
DE10148618B4
(de)
|
2001-09-25 |
2007-05-03 |
Schering Ag |
Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
|
US6706686B2
(en)
|
2001-09-27 |
2004-03-16 |
The Regents Of The University Of Colorado |
Inhibition of histone deacetylase as a treatment for cardiac hypertrophy
|
GB0123664D0
(en)
|
2001-10-02 |
2001-11-21 |
Inst Of Cancer Res The |
Histone deacetylase 9
|
CA2463552C
(en)
|
2001-10-16 |
2011-05-17 |
Sloan-Kettering Institute For Cancer Research |
Treatment of neurodegenerative diseases and cancer of the brain
|
WO2003033678A2
(en)
|
2001-10-18 |
2003-04-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Methods of using deacetylase inhibitors to promote cell differentiation and regeneration
|
CA2461373A1
(en)
|
2001-11-06 |
2003-05-15 |
Novartis Ag |
Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination
|
EP1453848A4
(en)
|
2001-11-21 |
2009-09-09 |
Einstein Coll Med |
PRODUCTS AND ACTIVITIES OF SIR2
|
WO2003046207A2
(en)
|
2001-11-27 |
2003-06-05 |
Fred Hutchinson Cancer Research Center |
Methods for inhibiting deacetylase activity
|
US20050227300A1
(en)
|
2001-12-07 |
2005-10-13 |
Atadja Peter W |
Use of alpha-tubulin acetylation levels as a biomarker for protein deacetylase inhibitors
|
AU2002351898A1
(en)
|
2001-12-21 |
2003-07-09 |
Universite Libre De Bruxelles |
Method for obtaining the elimination of integrated and functional viruses from infected mammal cells
|
WO2003057722A2
(en)
|
2001-12-28 |
2003-07-17 |
Fujisawa Pharmaceutical Co., Ltd. |
Cyclic tetrapeptide compound and use thereof
|
ITRM20020016A1
(it)
|
2002-01-15 |
2003-07-15 |
Sigma Tau Ind Farmaceuti |
Derivati di acidi fenil(alchil)carbossilici e derivati fenilalchileterociclici dionici, loro uso come medicamenti ad attivita' ipoglicemizza
|
US20030165956A1
(en)
|
2002-01-25 |
2003-09-04 |
Board Of Regents, The University Of Texas System |
Electrophoretic assay to predict risk of cancer and the efficacy and toxicity of cancer therapy
|
JP2005517007A
(ja)
|
2002-02-07 |
2005-06-09 |
アクシス・ファーマスーティカルズ |
ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
|
WO2003066885A2
(en)
|
2002-02-08 |
2003-08-14 |
Novartis Ag |
Method for screening for compounds having hdac inhibitory activity
|
JP2005525345A
(ja)
|
2002-02-15 |
2005-08-25 |
スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ |
Trx媒介性疾患を処置する方法
|
AU2003211576A1
(en)
|
2002-02-20 |
2003-09-09 |
Sueharu Horinouchi |
Histone deacetylase inhibitors and process for producing the same
|
AU2003211362A1
(en)
|
2002-02-21 |
2003-09-09 |
Osaka Industrial Promotion Organization |
N-hydroxycarboxamide derivative
|
US20040132825A1
(en)
|
2002-03-04 |
2004-07-08 |
Bacopoulos Nicholas G. |
Methods of treating cancer with HDAC inhibitors
|
AU2003213684C1
(en)
|
2002-03-04 |
2008-10-23 |
Merck Hdac Research, Llc |
Methods of inducing terminal differentiation
|
US7456219B2
(en)
|
2002-03-04 |
2008-11-25 |
Merck Hdac Research, Llc |
Polymorphs of suberoylanilide hydroxamic acid
|
US7148257B2
(en)
|
2002-03-04 |
2006-12-12 |
Merck Hdac Research, Llc |
Methods of treating mesothelioma with suberoylanilide hydroxamic acid
|
IL163732A0
(en)
|
2002-03-07 |
2005-12-18 |
Univ Johns Hopkins |
Genomic screen for epigenetically silenced tumor suppressor genes
|
AU2003230615A1
(en)
|
2002-03-07 |
2003-09-22 |
The Johns Hopkins University |
Genomic screen for epigenetically silenced genes associated with cancer
|
NZ534833A
(en)
|
2002-03-13 |
2006-07-28 |
Janssen Pharmaceutica Nv |
Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase (HDAC)
|
PL220783B1
(pl)
|
2002-03-13 |
2016-01-29 |
Janssen Pharmaceutica Nv |
Pochodna sulfonylowa, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
|
ATE521592T1
(de)
|
2002-03-13 |
2011-09-15 |
Janssen Pharmaceutica Nv |
Histone-deacetylase-inhibitoren
|
DE60321548D1
(de)
|
2002-03-13 |
2008-07-24 |
Janssen Pharmaceutica Nv |
Carbonylamino- derivativate als neue inhibitoren von histone deacetylase
|
BR0307599A
(pt)
|
2002-03-13 |
2005-02-01 |
Janssen Pharmaceutica Nv |
Derivados de sulfonilamino como inibidores de histona deacetilase
|
US20050009030A1
(en)
|
2002-03-26 |
2005-01-13 |
Fabien Schweighoffer |
Histone deacetylase: novel molecular target of neurotoxicity
|
AU2003226014A1
(en)
|
2002-03-28 |
2003-10-13 |
Brigham And Women's Hospital, Inc. |
Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease
|
US6841565B1
(en)
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
AU2003229883B2
(en)
|
2002-04-03 |
2009-06-11 |
Topotarget Uk Limited |
Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors
|
CA2481466A1
(en)
|
2002-04-05 |
2003-10-16 |
Yoshinori Naoe |
Depsipeptide for therapy of kidney cancer
|
TWI319387B
(en)
|
2002-04-05 |
2010-01-11 |
Astrazeneca Ab |
Benzamide derivatives
|
US7495022B2
(en)
|
2002-04-11 |
2009-02-24 |
Sk Chemicals Co., Ltd. |
α,β-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors
|
MY134200A
(en)
|
2002-04-12 |
2007-11-30 |
Kowa Co |
Method for treating cancer
|
WO2003088954A1
(en)
|
2002-04-15 |
2003-10-30 |
Sloan-Kettering Institute For Cancer Research |
Combination therapy for the treatment of cancer
|
US6620838B1
(en)
|
2002-04-19 |
2003-09-16 |
Signal Pharmaceuticals, Inc. |
Benzopyrazone compounds, compositions thereof, and methods of treatment therewith
|
US6809118B2
(en)
|
2002-07-25 |
2004-10-26 |
Yih-Lin Chung |
Methods for therapy of radiation cutaneous syndrome
|
US20030206946A1
(en)
|
2002-04-26 |
2003-11-06 |
Yih-Lin Chung |
Methods for therapy of connective tissue disease
|
GB0209715D0
(en)
|
2002-04-27 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
US20040018522A1
(en)
|
2002-05-09 |
2004-01-29 |
Brigham And Women's Hospital, Inc. |
Identification of dysregulated genes in patients with multiple sclerosis
|
EP1362914A3
(en)
|
2002-05-15 |
2004-05-06 |
Schering AG |
Histone deacetylase inhibitor and use thereof
|
US7351542B2
(en)
|
2002-05-20 |
2008-04-01 |
The Regents Of The University Of California |
Methods of modulating tubulin deacetylase activity
|
EP1511729A4
(en)
|
2002-05-22 |
2006-09-06 |
Errant Gene Therapeutics Llc |
HISTONDEACETYLASEINHIBITORS BASED ON ALPHACHALCOGEN METHYL CARBONYL COMPOUNDS
|
AU2003243272A1
(en)
|
2002-05-22 |
2003-12-12 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
|
WO2003099760A1
(en)
|
2002-05-22 |
2003-12-04 |
Errant Gene Therapeutics, Llc. |
Histone deacetylase inhibitors based on trihalomethylcarbonyl compounds
|
US20030224473A1
(en)
|
2002-05-23 |
2003-12-04 |
Mccafferty Dewey G. |
Methods for screening for histone deacetylase activity and for identifying histone deacetylase inhibitors
|
US7273713B2
(en)
|
2002-05-23 |
2007-09-25 |
The Regents Of The University Of California |
Methods of modulating mitochondrial NAD-dependent deacetylase
|
US20040002447A1
(en)
|
2002-06-04 |
2004-01-01 |
Regents Of The University Of California |
Induction of insulin expression
|
MXPA04012444A
(es)
|
2002-06-10 |
2005-04-19 |
Novartis Ag |
Combinaciones que comprenden epotilonas y sus usos farmaceuticos.
|
WO2004001072A2
(en)
|
2002-06-19 |
2003-12-31 |
Oncotherapy Science, Inc. |
Method for diagnosis of colorectal tumors
|
US20050084967A1
(en)
|
2002-06-28 |
2005-04-21 |
Xcyte Therapies, Inc. |
Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
|
MXPA05000256A
(es)
|
2002-07-01 |
2005-07-15 |
Upjohn Co |
Inhibidores de polimerasa ns5b del vhc.
|
US20040072770A1
(en)
|
2002-07-03 |
2004-04-15 |
Besterman Jeffrey M. |
Methods for specifically inhibiting histone deacetylase-7 and 8
|
SE0202157D0
(sv)
|
2002-07-09 |
2002-07-09 |
Biovitrum Ab |
Methods for identification of compounds modulating insulin resistance
|
GB0215844D0
(en)
|
2002-07-09 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
EP1534295A4
(en)
|
2002-07-17 |
2009-08-05 |
Chemgenex Pharmaceuticals Inc |
FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN
|
JP2006502117A
(ja)
|
2002-07-17 |
2006-01-19 |
タイタン ファーマシューティカルズ インコーポレイテッド |
抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ
|
DE10233412A1
(de)
|
2002-07-23 |
2004-02-12 |
4Sc Ag |
Neue Verbindungen als Histondeacetylase-Inhibitoren
|
US20050176686A1
(en)
|
2002-07-23 |
2005-08-11 |
4Sc Ag |
Novel compounds as histone deacetylase inhibitors
|
WO2004009771A2
(en)
|
2002-07-24 |
2004-01-29 |
Advanced Stent Technologies, Inc. |
Stents capable of controllably releasing histone deacetylase inhibitors
|
KR101083852B1
(ko)
|
2002-07-25 |
2011-11-15 |
소니 주식회사 |
유전자 전사 조절제 및 히스톤 탈아세틸화효소 저해 화합물의 스크리닝 방법
|
PL374970A1
(en)
|
2002-08-02 |
2005-11-14 |
Argenta Discovery Limited |
Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors
|
EP1547617B1
(en)
|
2002-08-20 |
2010-04-28 |
Astellas Pharma Inc. |
Arthrodial cartilage extracellular matrix degradation inhibitor
|
JP3987909B2
(ja)
|
2002-08-30 |
2007-10-10 |
アステラス製薬株式会社 |
新規なデプシペプチド化合物
|
CA2498210C
(en)
|
2002-09-13 |
2011-10-18 |
Virginia Commonwealth University |
Combination of a) n-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and b) a histone deacetylase inhibitor for the treatment of leukemia
|
EP1400806A1
(en)
|
2002-09-18 |
2004-03-24 |
G2M Cancer Drugs AG |
The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity
|
AU2003270668A1
(en)
|
2002-09-19 |
2004-04-08 |
University Of South Florida |
Method of treating leukemia with a combination of suberoylanilide hydromaxic acid and imatinib mesylate
|
EP1403639A1
(en)
|
2002-09-30 |
2004-03-31 |
G2M Cancer Drugs AG |
Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases
|
US20040077084A1
(en)
|
2002-10-17 |
2004-04-22 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 4 expression
|
US20040077083A1
(en)
|
2002-10-17 |
2004-04-22 |
Isis Pharmaceuticals Inc. |
Antisense modulation of histone deacetylase 4 expression
|
US7282608B2
(en)
*
|
2002-10-17 |
2007-10-16 |
Methylgene, Inc. |
Inhibitors of histone deacetylase
|
RU2352337C2
(ru)
|
2002-11-12 |
2009-04-20 |
Алькон, Инк. |
Ингибиторы гистондеацетилазы для лечения офтальмологических неоваскулярных нарушений и заболеваний
|
US20040092431A1
(en)
|
2002-11-12 |
2004-05-13 |
Hellberg Peggy E. |
Histone deacetylase inhibitors for treating degenerative diseases of the eye
|
WO2004046312A2
(en)
|
2002-11-15 |
2004-06-03 |
The Board Of Trustees Of The University Of Illinois |
Methods for in vitro expansion of hematopoietic stem cells
|
GB0226855D0
(en)
|
2002-11-18 |
2002-12-24 |
Queen Mary & Westfield College |
Histone deacetylase inhibitors
|
AU2003291097A1
(en)
|
2002-11-20 |
2004-06-15 |
Errant Gene Therapeutics, Llc |
Treatment of lung cells with histone deacetylase inhibitors
|
WO2004052292A2
(en)
|
2002-12-06 |
2004-06-24 |
University Of South Florida |
Histone deacetylase inhibitor enhancement of trail-induced apoptosis
|
TW200426138A
(en)
|
2002-12-10 |
2004-12-01 |
Hoffmann La Roche |
Novel arylene-carboxylic acid (2-amino-phenyl)-amide derivatives, their manufacture and use as pharmaceutical agents
|
EP1590318A2
(en)
|
2002-12-12 |
2005-11-02 |
Jawaharlal Nehru Centre For Advanced Scientific Research |
Modulators (inhibitors/activators) of histone acetyltransferases
|
TW200418825A
(en)
|
2002-12-16 |
2004-10-01 |
Hoffmann La Roche |
Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
|
ITMI20022745A1
(it)
|
2002-12-23 |
2004-06-24 |
Coimex Scrl United Companies |
Esteri misti dell'acido ialuronico ad attivita' citostatica e prodifferenziante e procedimento per la loro produzione.
|
EP1641458A2
(en)
*
|
2002-12-27 |
2006-04-05 |
Schering Aktiengesellschaft |
Pharmaceutical combinations of phthalazine vegf inhibitors and benzamide hdac inhibitors
|
US20040197888A1
(en)
|
2002-12-31 |
2004-10-07 |
Armour Christopher D. |
Alternatively spliced isoforms of histone deacetylase 3 (HDAC3)
|
ITMI20030025A1
(it)
|
2003-01-10 |
2004-07-11 |
Italfarmaco Spa |
Derivati dell'acido idrossammico ad attivita' antinfiammatoria.
|
TW200418806A
(en)
|
2003-01-13 |
2004-10-01 |
Fujisawa Pharmaceutical Co |
HDAC inhibitor
|
WO2004064727A2
(en)
|
2003-01-16 |
2004-08-05 |
Georgetown University |
Method of cancer treatment using hdac inhibitors
|
CA2513246A1
(en)
|
2003-01-17 |
2004-08-05 |
Topotarget Uk Limited |
Carbamic acid compounds comprising an ester or ketone linkage as hdac inhibitors
|
WO2004067480A2
(en)
|
2003-01-25 |
2004-08-12 |
Oxford Glycosciences (Uk) Ltd |
Substituted phenylurea derivatives as hdac inhibitors
|
TW200424174A
(en)
|
2003-02-06 |
2004-11-16 |
Hoffmann La Roche |
New TP diamide
|
US7208491B2
(en)
*
|
2003-02-07 |
2007-04-24 |
Hoffmann-La Roche Inc. |
N-monoacylated o-phenylenediamines
|
CA2515677A1
(en)
|
2003-02-11 |
2004-08-26 |
Wyeth |
Methods for monitoring drug activities in vivo
|
AU2003900608A0
(en)
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
AU2003900587A0
(en)
|
2003-02-11 |
2003-02-27 |
Fujisawa Pharmaceutical Co., Ltd. |
Hdac inhibitor
|
WO2004071443A2
(en)
|
2003-02-12 |
2004-08-26 |
Irm Llc |
Methods and compositions for modulating stem cells
|
WO2004071464A2
(en)
|
2003-02-12 |
2004-08-26 |
Johns Hopkins University School Of Medicine |
Diagnostic application of differentially-expressed genes in lympho-hematopoietic stem cells
|
US7244751B2
(en)
|
2003-02-14 |
2007-07-17 |
Shenzhen Chipscreen Biosciences Ltd. |
Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
|
EP1595952A4
(en)
|
2003-02-19 |
2008-05-21 |
Astellas Pharma Inc |
METHOD FOR EVALUATING THE ANTITUMOR EFFECT OF A HISTONE DEACETYLASE INHIBITOR
|
AU2004215624B2
(en)
|
2003-02-25 |
2011-06-02 |
Topotarget Uk Limited |
Hydroxamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
|
US7381825B2
(en)
|
2003-03-17 |
2008-06-03 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2004089293A2
(en)
|
2003-04-01 |
2004-10-21 |
Memorial Sloan-Kettering Cancer Center |
Hydroxamic acid compounds and methods of use thereof
|
TW200424187A
(en)
|
2003-04-04 |
2004-11-16 |
Hoffmann La Roche |
New oxime derivatives and their use as pharmaceutically active agents
|
ES2328819T3
(es)
|
2003-04-07 |
2009-11-18 |
Pharmacyclics, Inc. |
Hidroxamatos como agentes terapeuticos.
|
US20040213826A1
(en)
|
2003-04-28 |
2004-10-28 |
Marx Steven O. |
Medical devices and methods for inhibiting proliferation of smooth muscle cells
|
CA2526908A1
(en)
|
2003-05-21 |
2004-12-02 |
Novartis Ag |
Combination of histone deacetylase inhibitors with chemotherapeutic agents
|
CN1812776A
(zh)
|
2003-05-21 |
2006-08-02 |
得克萨斯州大学系统董事会 |
抑制蛋白激酶c-mu(pkd)用作心脏肥大和心力衰竭的疗法
|
PE20050206A1
(es)
|
2003-05-26 |
2005-03-26 |
Schering Ag |
Composicion farmaceutica que contiene un inhibidor de histona deacetilasa
|
US20050020557A1
(en)
|
2003-05-30 |
2005-01-27 |
Kosan Biosciences, Inc. |
Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
|
BRPI0411275A
(pt)
|
2003-06-10 |
2006-08-01 |
Kalypsys Inc |
compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
|
US7271195B2
(en)
|
2003-06-10 |
2007-09-18 |
Kalypsys, Inc. |
Carbonyl compounds as inhibitors of histone deacetylase for the treatment of disease
|
EP1633751A1
(en)
|
2003-06-16 |
2006-03-15 |
Chroma Therapeutics Limited |
Carboline and betacarboline derivatives for use as hdac enzyme inhibitors
|
EP1491188A1
(en)
|
2003-06-25 |
2004-12-29 |
G2M Cancer Drugs AG |
Topical use of valproic acid for the prevention or treatment of skin disorders
|
CA2529840A1
(en)
|
2003-06-27 |
2005-01-06 |
Astellas Pharma Inc. |
Therapeutic agent for soft tissue sarcoma
|
AU2004253579B2
(en)
|
2003-07-01 |
2010-12-23 |
Biomol International L.P. |
Sirt1 modulators for manipulating cells/organism lifespan/stress response
|
US8383653B2
(en)
|
2003-07-02 |
2013-02-26 |
Albert Einstein College Of Medicine Of Yeshiva University |
SIR2 regulation
|
US7842835B2
(en)
|
2003-07-07 |
2010-11-30 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
EP1644323B1
(en)
|
2003-07-07 |
2015-03-18 |
Georgetown University |
Histone deacetylase inhibitors and methods of use thereof
|
US7723376B2
(en)
|
2003-07-15 |
2010-05-25 |
Korea Research Institute Of Bioscience And Biotechnology |
2-oxo-heterocyclic compounds and pharmaceutical compositions
|
GB0316889D0
(en)
|
2003-07-18 |
2003-08-20 |
Univ London |
Pharmaceutical agents
|
US20050037992A1
(en)
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
WO2005011598A2
(en)
|
2003-07-31 |
2005-02-10 |
University Of South Florida |
Leukemia treatment method and composition
|
WO2005014588A1
(en)
|
2003-08-01 |
2005-02-17 |
Argenta Discovery Limited |
Substituted thienyl-hydroxamic acids having histone deacetylase activity
|
US20050032794A1
(en)
|
2003-08-05 |
2005-02-10 |
Padia Janak K. |
Diamine derivatives of quinone and uses thereof
|
WO2005013958A1
(en)
|
2003-08-07 |
2005-02-17 |
Novartis Ag |
Histone deacetylase inhibitors as immunosuppressants
|
CN100536850C
(zh)
|
2003-08-08 |
2009-09-09 |
诺瓦提斯公司 |
包含星孢素的组合
|
JP2007502838A
(ja)
|
2003-08-20 |
2007-02-15 |
アクシス・ファーマシューティカルズ・インコーポレイテッド |
ヒストンデアセチラーゼのインヒビターとしてのアセチレン誘導体
|
EP1663194B1
(en)
|
2003-08-26 |
2010-03-31 |
Merck HDAC Research, LLC |
Use of SAHA for treating mesothelioma
|
CN102349927A
(zh)
|
2003-08-29 |
2012-02-15 |
Hdac默克研究有限责任公司 |
联合治疗癌症的方法
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
WO2005028620A2
(en)
|
2003-09-16 |
2005-03-31 |
The Rockefeller University |
Histone modifications as binary switches controlling gene expression
|
AU2004271730A1
(en)
|
2003-09-18 |
2005-03-24 |
Novartis Ag |
Combination of a histone deacetylase inhibitor with a death receptor ligand
|
US7781595B2
(en)
|
2003-09-22 |
2010-08-24 |
S*Bio Pte Ltd. |
Benzimidazole derivatives: preparation and pharmaceutical applications
|
KR101153335B1
(ko)
|
2003-09-24 |
2012-07-05 |
메틸진 인코포레이티드 |
히스톤 데아세틸라제의 억제제
|
ES2344899T3
(es)
|
2003-09-25 |
2010-09-09 |
Astellas Pharma Inc. |
Agente antitumoral que comprende un inhibidor de histona desacetilasa y un inhibidor de topoisomerasa ii.
|
EP1677731A4
(en)
|
2003-10-09 |
2009-05-06 |
Aton Pharma Inc |
THIOPHENE AND BENZOTHIOPHENE DERIVATIVES OF HYDROXAMIC ACID
|
US20050124625A1
(en)
|
2003-10-21 |
2005-06-09 |
Salvati Mark E. |
Piperazine derivatives and their use as modulators of nuclear hormone receptor function
|
AR046605A1
(es)
|
2003-10-27 |
2005-12-14 |
S Bio Pte Ltd |
Hidroxamatos unidos a biarilo; preparacion y aplicaciones farmaceuticas
|
AR046920A1
(es)
|
2003-10-27 |
2006-01-04 |
S Bio Pte Ltd |
Hidroxamatos conectados a acilurea y conectado a sulfonilurea
|
IN2003CH00929A
(es)
|
2003-11-13 |
2008-10-06 |
|
|
WO2005053609A2
(en)
|
2003-11-26 |
2005-06-16 |
Guilford Pharmaceuticals Inc. |
Methods of nad+-dependent deacetylase inhibitors
|
EP1694329A4
(en)
|
2003-11-26 |
2009-06-03 |
Aton Pharma Inc |
DIAMOND AND IMINODIACETIC ACID HYDROXAMINIC DERIVATIVES
|
US20080004290A1
(en)
|
2003-11-28 |
2008-01-03 |
The University Of Queensland |
Anti-Cancer Agents
|
CA2552279C
(en)
|
2003-12-02 |
2014-07-15 |
The Ohio State University Research Foundation |
Zn2+-chelating motif-tethered short -chain fatty acids as a novel class of histone deacetylase inhibitors
|
WO2005058298A2
(en)
|
2003-12-10 |
2005-06-30 |
Wisconsin Alumni Research Foundation |
Fk228 analogs and their use as hdac-inhibitors
|
EP1541549A1
(en)
|
2003-12-12 |
2005-06-15 |
Exonhit Therapeutics S.A. |
Tricyclic hydroxamate and benzaminde derivatives, compositions and methods
|
WO2005066151A2
(en)
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
Histone deacetylase inhibitors
|
WO2005065681A1
(en)
|
2003-12-19 |
2005-07-21 |
Takeda San Diego, Inc. |
N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
|
US8652502B2
(en)
|
2003-12-19 |
2014-02-18 |
Cordis Corporation |
Local vascular delivery of trichostatin A alone or in combination with sirolimus to prevent restenosis following vascular injury
|
AU2004312072B2
(en)
|
2003-12-29 |
2011-06-23 |
President And Fellows Of Harvard College |
Compositions for treating or preventing obesity and insulin resistance disorders
|
US20090253769A1
(en)
|
2004-01-21 |
2009-10-08 |
Gessica Filocamo |
Inhibitors of mammalian hdac 11 useful for treating hdac 11 mediated disorders
|
EP1735319B1
(en)
|
2004-03-26 |
2017-05-03 |
MethylGene Inc. |
Inhibitors of histone deacetylase
|
US7253204B2
(en)
|
2004-03-26 |
2007-08-07 |
Methylgene Inc. |
Inhibitors of histone deacetylase
|